Literature DB >> 12930373

Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis.

H Takada1, Y Takahata, A Nomura, S Ohga, Y Mizuno, T Hara.   

Abstract

We measured serum interferon-gamma-inducible protein 10 (IP-10) and monokine induced by gamma interferon (MIG) levels to investigate the role of these molecules in the pathophysiology of haemophagocytic lymphohistiocytosis (HLH). Serum IP-10 and MIG levels were significantly increased in patients with active HLH compared with those of healthy controls. Serum MIG levels decreased gradually during the course of disease in a patient who recovered without therapy. On the other hand, rapid reduction of MIG and IP-10 levels was observed after chemotherapy in a patient with severe HLH. IP-10 and MIG mRNA expression was enhanced in liver and spleen, and IP-10 mRNA expression was enhanced in bone marrow in the patients, suggesting activated macrophages that infiltrated in these organs as one of the main producers of these cytokines. Serum IP-10 and MIG levels showed a significant correlation with serum IFN-gamma levels. In addition, these chemokines had a significant correlation with fever and serum LDH levels, which are clinical indicators of disease activity of HLH. These results suggest that IP-10 and MIG which are produced by activated macrophages by the stimulation of IFN-gamma, play an important role in the pathophysiology of HLH, by recruitment of activated Th1 cells into the tissues or organs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930373      PMCID: PMC1808805          DOI: 10.1046/j.1365-2249.2003.02237.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

Review 1.  Chemokines and disease.

Authors:  C Gerard; B J Rollins
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

2.  Robust expression of TNF-alpha, IL-1beta, RANTES, and IP-10 by human microglial cells during nonproductive infection with herpes simplex virus.

Authors:  J R Lokensgard; S Hu; W Sheng; M vanOijen; D Cox; M C Cheeran; P K Peterson
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

3.  CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis.

Authors:  B T Fife; K J Kennedy; M C Paniagua; N W Lukacs; S L Kunkel; A D Luster; W J Karpus
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

Review 4.  Chemokine receptors and their role in inflammation and infectious diseases.

Authors:  C Murdoch; A Finn
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

5.  Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.

Authors:  P L Shields; C M Morland; M Salmon; S Qin; S G Hubscher; D H Adams
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

6.  Overexpression of interferon gamma-inducible protein 10 in the liver of patients with type I autoimmune hepatitis identified by suppression subtractive hybridization.

Authors:  K Nagayama; N Enomoto; Y Miyasaka; M Kurosaki; C H Chen; N Sakamoto; M Nakagawa; C Sato; J Tazawa; T Ikeda; N Izumi; M Watanabe
Journal:  Am J Gastroenterol       Date:  2001-07       Impact factor: 10.864

7.  The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3.

Authors:  P Loetscher; A Pellegrino; J H Gong; I Mattioli; M Loetscher; G Bardi; M Baggiolini; I Clark-Lewis
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

8.  Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions.

Authors:  J E Simpson; J Newcombe; M L Cuzner; M N Woodroofe
Journal:  Neuropathol Appl Neurobiol       Date:  2000-04       Impact factor: 8.090

9.  Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease.

Authors:  Paola Romagnani; Mario Rotondi; Elena Lazzeri; Laura Lasagni; Michela Francalanci; Andrea Buonamano; Stefano Milani; Paolo Vitti; Luca Chiovato; Massimo Tonacchera; Antonio Bellastella; Mario Serio
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

10.  Requirement of the chemokine receptor CXCR3 for acute allograft rejection.

Authors:  W W Hancock; B Lu; W Gao; V Csizmadia; K Faia; J A King; S T Smiley; M Ling; N P Gerard; C Gerard
Journal:  J Exp Med       Date:  2000-11-20       Impact factor: 14.307

View more
  24 in total

1.  Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.

Authors:  Asra Ahmed; Samuel A Merrill; Fares Alsawah; Paula Bockenstedt; Erica Campagnaro; Sumana Devata; Scott D Gitlin; Mark Kaminski; Alice Cusick; Tycel Phillips; Suman Sood; Moshe Talpaz; Albert Quiery; Philip S Boonstra; Ryan A Wilcox
Journal:  Lancet Haematol       Date:  2019-09-16       Impact factor: 18.959

2.  Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis.

Authors:  Romain Lévy; Mathieu Fusaro; Frédéric Guerin; Ahmed Chetouani; Despina Moshous; Alain Fischer; Geneviève de Saint Basile; Fernando E Sepulveda; Bénédicte Neven
Journal:  Blood Adv       Date:  2020-04-14

3.  Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition.

Authors:  Scott W Canna; Charlotte Girard; Louise Malle; Adriana de Jesus; Neil Romberg; Judith Kelsen; Lea F Surrey; Pierre Russo; Andrew Sleight; Eduardo Schiffrin; Cem Gabay; Raphaela Goldbach-Mansky; Edward M Behrens
Journal:  J Allergy Clin Immunol       Date:  2016-11-19       Impact factor: 10.793

Review 4.  Pathophysiology of Pediatric Multiple Organ Dysfunction Syndrome.

Authors:  Joseph A Carcillo; Bradley Podd; Rajesh Aneja; Scott L Weiss; Mark W Hall; Timothy T Cornell; Thomas P Shanley; Lesley A Doughty; Trung C Nguyen
Journal:  Pediatr Crit Care Med       Date:  2017-03       Impact factor: 3.624

Review 5.  Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Annu Rev Med       Date:  2014-11-05       Impact factor: 13.739

Review 6.  Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.

Authors:  Lauren A Henderson; Randy Q Cron
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

7.  Interferon-γ mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice.

Authors:  Scott W Canna; Julia Wrobel; Niansheng Chu; Portia A Kreiger; Michele Paessler; Edward M Behrens
Journal:  Arthritis Rheum       Date:  2013-07

Review 8.  Macrophage activation syndrome and cytokine-directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Best Pract Res Clin Rheumatol       Date:  2014-04       Impact factor: 4.098

Review 9.  Macrophage activation syndrome in the era of biologic therapy.

Authors:  Alexei A Grom; AnnaCarin Horne; Fabrizio De Benedetti
Journal:  Nat Rev Rheumatol       Date:  2016-03-24       Impact factor: 20.543

10.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  David T Teachey; Simon F Lacey; Pamela A Shaw; J Joseph Melenhorst; Shannon L Maude; Noelle Frey; Edward Pequignot; Vanessa E Gonzalez; Fang Chen; Jeffrey Finklestein; David M Barrett; Scott L Weiss; Julie C Fitzgerald; Robert A Berg; Richard Aplenc; Colleen Callahan; Susan R Rheingold; Zhaohui Zheng; Stefan Rose-John; Jason C White; Farzana Nazimuddin; Gerald Wertheim; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  Cancer Discov       Date:  2016-04-13       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.